Who makes Rhustoxicodendron 30?

Rhustoxicodendron 30 is developed by Healthcare Homoeo Charitable Society.

What development phase is Rhustoxicodendron 30 in?

Rhustoxicodendron 30 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Rhustoxicodendron 30

Healthcare Homoeo Charitable Society · Phase 2 active Small molecule

At a glance

Generic name	Rhustoxicodendron 30
Also known as	poison ivy
Sponsor	Healthcare Homoeo Charitable Society
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rhustoxicodendron 30 CI brief — competitive landscape report
Rhustoxicodendron 30 updates RSS · CI watch RSS
Healthcare Homoeo Charitable Society portfolio CI